Name: 글로벌 시장 동향
SKU: PH7725
Availability: InStock

보고서 요약(국문)

개요
전 세계 코카인 중독 치료제 시장은 2022년 XX백만 달러에 달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) XX%로 성장하여 2030년에는 XX백만 달러에 이를 것으로 예상됩니다.
코카인 중독은 약물 사용으로 인한 쾌감뿐만 아니라 신체 전반에 걸친 증상으로 인해 신체 기능이 저하되는 상태를 말합니다. 코카인 중독은 행복감, 명료함, 만족감, 에너지, 자신감 등의 "쾌감"으로 묘사됩니다. 편집증, 소리와 빛에 대한 과민 반응, 심박수 증가, 혈압 상승, 동공 확장과 같은 증상도 나타날 수 있습니다.
코카인 남용은 짧은 간격(5~30분)으로 반복적으로 투여되는 폭음-급성 탈진 주기와 같은 패턴을 보입니다. 일단 코카인 사용이 시작되면, 그 직후에 더 많은 코카인을 사용할 가능성이 매우 높습니다. 코카인 사용이 끝나면 불안감, 과민성, 우울증 등으로 특징지어지는 "크래시(crash)" 현상이 나타날 수 있습니다.
시장 동향: 동인 및 제약 요인
코카인 남용에 대한 인식 제고
인식 제고 캠페인은 대중, 특히 젊은층에게 코카인 사용의 위험성과 결과에 대해 교육할 수 있습니다. 학교, 지역사회, 직장에서의 예방 프로그램은 약물 남용의 위험성을 강조하고 건강한 대안을 제시할 수 있습니다.
예를 들어, 미국 질병통제예방센터(CDC)는 2021년 10월 18세에서 34세 사이의 젊은 성인을 대상으로 하는 네 가지 보완적인 교육 캠페인을 시작했습니다. 이 캠페인은 펜타닐의 유병률과 위험성, 약물 혼합의 위험성과 결과, 날록손의 생명을 구하는 효능, 그리고 치료와 회복을 지원하기 위해 약물 사용에 대한 사회적 낙인을 줄이는 것의 중요성에 대한 정보를 제공합니다.
CDC는 이 캠페인을 개발하기 위해 약물 사용 경험이 있다고 보고한 젊은 성인들과 동료 회복 전문가들과 직접 소통했습니다. 각 캠페인은 사람들이 정보에 입각한 결정을 내리고 필요한 도움을 받아 궁극적으로 약물 과다 복용 및 과다 복용으로 인한 사망자 증가를 줄일 수 있도록 네 가지 주제 모두에 대한 새로운 자료를 제공합니다.
더 효과적인 치료법이 개발됨에 따라 코카인 중독 환자는 더 나은 건강 결과와 삶의 질을 경험할 수 있습니다. 이는 치료 옵션에 대한 수요를 증가시키고 시장 성장을 더욱 촉진할 수 있습니다.
또한 코카인 중독 치료제 시장은 지속적인 연구 개발과 같은 다양한 요인에 의해 성장하고 있으며, 이는 코카인 중독 환자 및 기타 환자를 위한 새롭고 개선된 치료 옵션의 가능성을 높이고 있습니다.
시장 동향: 제약 요인
시장은 코카인 중독 치료 옵션의 제한된 가용성과 높은 비용과 같은 어려운 요인에 의해 상당한 영향을 받을 것으로 예상됩니다. 입원, 집중 치료 또는 특수 진단 검사와 같은 고가의 치료 및 관련 비용은 시장 성장을 저해할 것으로 예상됩니다.
세분화 분석
전 세계 코카인 중독 치료제 시장은 약물 종류, 투여 경로, 유통 채널 및 지역별로 세분화됩니다.

약물 계열 중 디아제팜은 코카인 중독 치료제 시장 점유율의 약 45.5%를 차지했습니다.
디아제팜은 약 45.5%의 점유율을 차지하며 예측 기간 동안 시장을 주도할 것으로 예상됩니다. 디아제팜은 코카인 중독에 대한 해독제 역할을 하는 것으로 보이며, 코카인 관련 응급 상황에 대처하는 유용한 전략이 될 수 있습니다. 코카인 중독에 대한 약물 치료적 개입에서 디아제팜과 같은 벤조디아제핀은 코카인의 중추신경계 효과를 줄이고 임상적으로 중요한 빈맥과 고혈압을 조절하는 데 권장됩니다.
하지만 코카인을 남용하는 일부 환자는 벤조디아제핀에 대한 민감도가 높아질 수 있으므로 혈관 활성제 및 항고혈압제를 사용할 때는 활력 징후를 면밀히 모니터링하는 것이 중요합니다.

지리적 분석
북미는 2022년 시장 점유율의 약 38.4%를 차지했습니다.
북미는 연구 개발의 발전, FDA 승인, 선진 의료 인프라 등의 요인으로 인해 예측 기간 동안 전체 시장 점유율의 약 38.4%를 차지할 것으로 예상됩니다.
예를 들어, 2022년 7월 뉴욕에 본사를 둔 회사는 주요 우울 장애(MDD)에 대한 중기 임상 연구를 발표했으며, 이는 6월에 발표된 코카인 중독 치료를 위한 2상 임상 연구에 이은 것이었습니다. MDD의 잠재적 치료제로 실험적인 서방형(ER) 치료제인 TNX-601 ER(티아넵틴 옥살레이트 서방형)의 2상 임상 연구를 진행할 계획입니다. TNX-601 ER은 FDA 승인 의약품에서는 볼 수 없었던 제형으로 기존의 선택적 세로토닌 재흡수 억제제(SSRI) 치료 요법과 차별화됩니다.
코로나19 영향 분석
코로나19 팬데믹은 코카인 중독에는 제한적인 영향을 미쳤지만, 약물 사용 장애와 합성 칸나비노이드 사용의 증가를 초래했습니다. 또한 팬데믹은 마약 시장에도 영향을 미쳐 일부 국가에서는 마약 밀매와 재배가 증가했습니다.

코로나19 시장 세분화
약물 종류별
• 디아제팜
• 모르핀
• 펜톨아민
• 로라제팜
• 베라파밀
투여 경로별
• 정맥 주사
• 비강 투여
• 경구 투여
유통 채널별
• 병원 약국
• 소매 약국
• 온라인 약국
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 이탈리아
o 스페인
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
경쟁 환경
시장의 주요 글로벌 업체로는 Tonix Pharmaceutical, GlaxoSmithKline Plc, Bristol Myers Squibb Company, Pfizer Inc, Novartis AG, Teva Pharmaceuticals Ltd, Zydus Pharmaceuticals, Inc, Sun Pharmaceuticals Industries 등이 있습니다. Ltd, Advanz Pharmaceuticals, AdvaCare Pharma 등을 포함합니다.
주요 개발 사항
 2022년 6월, 임상 단계 바이오제약 회사인 Tonix Pharmaceuticals Holding Corp는 코카인 중독 치료를 위한 TNX-1300(T172R/G173Q 이중 돌연변이 코카인 에스테라제 200mg, 정맥 주사액)의 새로운 2상 임상 시험 설계를 발표했습니다. 이 새로운 프로토콜은 중요한 임상 시험이 될 가능성이 있습니다.
TNX-1300은 코카인 사용자의 코카인을 효율적으로 분해 및 대사하는 재조합 효소로, 이전의 2a상 무작위 이중맹검 위약 대조 임상 연구에서 입증되었으며, 코카인 중독 치료제로서 TNX-1300의 사용을 뒷받침합니다.
이 보고서를 구매해야 하는 이유?

• 약물 종류, 투여 경로, 유통 채널 및 지역별 글로벌 코카인 중독 치료제 시장 세분화를 시각화하고 주요 상업 자산 및 주요 업체를 파악합니다.

• 트렌드 및 공동 개발 분석을 통해 사업 기회를 발굴합니다.

• 모든 세그먼트를 포함한 코카인 중독 치료제 시장 수준의 다양한 데이터가 담긴 엑셀 자료를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 포함한 제품 맵핑 자료를 엑셀 파일로 제공합니다.

글로벌 코카인 중독 치료제 시장 보고서는 약 77개의 표, 79개의 그림, 187페이지 분량입니다.
대상 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Cocaine Intoxication Drugs Market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing with a CAGR of XX % during the forecast period 2023-2030.
Cocaine intoxication is a condition in the person not only high from using the drug but also have body-wide symptoms that can make the person ill and impaired. Cocaine intoxication has been described as a “rush,” including feelings of elation, clarity, well-being, energy, and confidence. Symptoms such as paranoia, intensified sounds and light sensitivity may also occur, as well as increased heart rate, blood pressure, and pupil dilation.
The pattern in which cocaine is abused is in bouts or binge-crash cycles, where doses are repeatedly administered with short inter-dose intervals (5–30 min). Once cocaine use is initiated, the probability is high that more cocaine will be used shortly after that. After the termination of a bout of cocaine use, there may be a period described as a “crash,” characterised by anxiety, irritability, and depression.
Market Dynamics: Drivers and Restraints
Rise in awareness regarding the overuse of cocaine
Awareness campaigns can educate the public, especially young people, about the risks and consequences of cocaine use. Prevention programs in schools, communities, and workplaces can emphasize the dangers of drug abuse and promote healthy alternatives.
For instance, in October 2021, the Centers for Disease Control and Prevention (CDC) launched four complementary education campaigns intended to reach young adults ages 18 to 34 years. The campaigns provide information about the prevalence and dangers of fentanyl, the risks and consequences of mixing drugs, the life-saving power of naloxone, and the importance of reducing stigma around drug use to support treatment and recovery.
CDC spoke directly with young adults who reported using drugs, as well as peer recovery professionals, to develop the campaigns. Each campaign includes new resources on all four topics to help people make informed decisions, get the help they need, and ultimately reduce the rise in drug overdoses and overdose deaths.
As more effective treatments become available, patients with Cocaine Intoxication may experience better health outcomes and quality of life. This could increase demand for management options and further drive market growth.
Furthermore, the cocaine intoxication drugs market is also driven by various other factors like ongoing research and development, which is leading to an increased potential for new and improved treatment options to become available for patients with Cocaine Intoxication and others.
Market Dynamics: Restraint
The market is projected to be significantly affected by challenging factors such as limited availability and high cost of advanced cocaine intoxication treatment options. Expensive treatments and related costs such as hospitalization, intensive care, or specialized diagnostic tests, is expected to hinder the market growth.
Segment Analysis
The global cocaine intoxication drugs market is segmented based on drug class, route of administration, distribution channel and region.
The diazepam from the drug class segment accounted for approximately 45.5% of the cocaine intoxication drugs market share
The diazepam from the drug class segment accounted for approximately 45.5% and is expected to dominate during the forecast period. Diazepam appears to be an antidote against this toxicity, suggesting a useful potential strategy for dealing with coca tropine-related hospital emergencies. In the context of pharmacotherapeutic intervention in cocaine toxicity, benzodiazepines such as diazepam are recommended to reduce the central nervous system effects of the drug and to control clinically significant tachycardia and hypertension.
However, it is important to note that some patients who abuse cocaine may have enhanced sensitivity to benzodiazepines, and close monitoring of vital signs is recommended when using vasoactive and antihypertensive medications.
Geographical Analysis
North America accounted for approximately 38.4% of the market share in 2022
North America is estimated to hold about 38.4% of the total market share throughout the forecast period, owing to the factors like advancements in research and developments, FDA approvals, advanced healthcare infrastructure and others that help this region to have the highest market share during the forecast period.
For instance, in July 2022, The New York-based company announced a mid-stage study for major depressive disorder (MDD), which followed the June disclosure of a planned Phase II study for a cocaine intoxication therapy. Plans are in the works to conduct a Phase II study of experimental extended-release (ER) treatment TNX-601 ER, or tianeptine oxalate extended-release, as a potential treatment for MDD. TNX-601 ER sets itself apart from the usual selective serotonin reuptake inhibitor (SSRI) treatment regimens with a formulation unseen in FDA-approved drugs.
COVID-19 Impact Analysis
The COVID-19 pandemic has had a limited impact on cocaine intoxication, but it has led to an increase in drug use disorders and the use of synthetic cannabinoids. The pandemic has also affected drug markets, with some countries experiencing an increase in drug trafficking and cultivation.
Market Segmentation
By Drug Class
• Diazepam
• Morphine
• Phentolamine
• Lorazepam
• Verapamil
By Route of Administration
• Intravenous
• Nasal
• Oral
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the market include Tonix Pharmaceutical, GlaxoSmithKline Plc, Bristol Myers Squibb Company, Pfizer Inc, Novartis AG, Teva Pharmaceuticals Ltd, Zydus Pharmaceuticals, Inc, Sun Pharmaceuticals Industries Ltd, Advanz Pharmaceuticals, AdvaCare Pharma and among others.
Key Developments
 In June 2022, Tonix Pharmaceuticals Holding Corp, a clinical-stage biopharmaceutical company, stated the design of a new Phase 2 clinical trial of TNX-1300 (T172R/G173Q double-mutant cocaine esterase 200 mg, i.v. solution) for the treatment of cocaine intoxication. This new protocol has the potential to serve as a pivotal trial.
TNX-1300 is a recombinant enzyme that efficiently degrades and metabolizes cocaine in cocaine users, as demonstrated in a prior Phase 2a randomized, double-blind, placebo-controlled clinical study, providing support for the use of TNX-1300 as a treatment for cocaine intoxication.
Why Purchase the Report?
• To visualize the global cocaine intoxication drugs market segmentation based on drug class, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analysing trends and co-development.
• Excel data sheet with numerous data points of cocaine intoxication drugs market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global cocaine intoxication drugs market report would provide approximately 77 tables, 79 figures and 187 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Drug Class
3.2. Snippet by Route of Administration
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Market Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rise in the awareness regarding the overuse of cocaine
4.1.1.2. Rise in the research and development
4.1.2. Restraints
4.1.2.1. High cost of treatment
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Drug Class
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
7.1.2. Market Attractiveness Index, By Drug Class
7.2. Diazepam*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Morphine
7.4. Phentolamine
7.5. Lorazepam
7.6. Verapamil
8. By Route of Administration
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.1.2. Market Attractiveness Index, By Route of Administration
8.2. Intravenous*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Nasal
8.4. Oral
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacies *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacies
9.4. Online Pharmacies
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.5.1. China
10.5.5.2. India
10.5.5.3. Japan
10.5.5.4. Australia
10.5.5.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Tonix Pharmaceutical*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. GlaxoSmithKline Plc
12.3. Bristol Myers Squibb Company
12.4. Pfizer Inc
12.5. Novartis AG
12.6. Teva Pharmaceuticals Ltd
12.7. Zydus Pharmaceuticals, Inc
12.8. Sun Pharmaceuticals Industries Ltd
12.9. Advanz Pharmaceuticals
12.10. AdvaCare Pharma
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Tonix Pharmaceutical, 4.	Key Developments, GlaxoSmithKline Plc, Bristol Myers Squibb Company, Pfizer Inc, Novartis AG, Teva Pharmaceuticals Ltd, Zydus Pharmaceuticals, Inc, Sun Pharmaceuticals Industries Ltd, Advanz Pharmaceuticals, AdvaCare Pharma

표 목록 (Tables)

List of Tables

Table 1 Global Cocaine Intoxication Drugs Market Value, By Drug Class, 2022, 2026 & 2030 (US$ Million)

Table 2 Global Cocaine Intoxication Drugs Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 3 Global Cocaine Intoxication Drugs Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 4 Global Cocaine Intoxication Drugs Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 5 Global Cocaine Intoxication Drugs Market Value, By Drug Class, 2022, 2026 & 2030 (US$ Million)

Table 6 Global Cocaine Intoxication Drugs Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 7 Global Cocaine Intoxication Drugs Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 8 Global Cocaine Intoxication Drugs Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 9 Global Cocaine Intoxication Drugs Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 10 Global Cocaine Intoxication Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 11 Global Cocaine Intoxication Drugs Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 12 Global Cocaine Intoxication Drugs Market Value, By Region, 2021-2030 (US$ Million)

Table 13 North America Cocaine Intoxication Drugs Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 14 North America Cocaine Intoxication Drugs Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 15 North America Cocaine Intoxication Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 16 North America Cocaine Intoxication Drugs Market Value, By Country, 2021-2030 (US$ Million)

Table 17 South America Cocaine Intoxication Drugs Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 18 South America Cocaine Intoxication Drugs Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 19 South America Cocaine Intoxication Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 20 South America Cocaine Intoxication Drugs Market Value, By Country, 2021-2030 (US$ Million)

Table 21 Europe Cocaine Intoxication Drugs Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 22 Europe Cocaine Intoxication Drugs Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 23 Europe Cocaine Intoxication Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 24 Europe Cocaine Intoxication Drugs Market Value, By Country, 2021-2030 (US$ Million)

Table 25 Asia-Pacific Cocaine Intoxication Drugs Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 26 Asia-Pacific Cocaine Intoxication Drugs Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 27 Asia-Pacific Cocaine Intoxication Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 28 Asia-Pacific Cocaine Intoxication Drugs Market Value, By Country, 2021-2030 (US$ Million)

Table 29 Middle East & Africa Cocaine Intoxication Drugs Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 30 Middle East & Africa Cocaine Intoxication Drugs Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 31 Middle East & Africa Cocaine Intoxication Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 32 Tonix Pharmaceutical: Overview

Table 33 Tonix Pharmaceutical: Product Portfolio

Table 34 Tonix Pharmaceutical: Key Developments

Table 35 GlaxoSmithKline Plc: Overview

Table 36 GlaxoSmithKline Plc: Product Portfolio

Table 37 GlaxoSmithKline Plc: Key Developments

Table 38 Bristol Myers Squibb Company: Overview

Table 39 Bristol Myers Squibb Company: Product Portfolio

Table 40 Bristol Myers Squibb Company: Key Developments

Table 41 Pfizer Inc: Overview

Table 42 Pfizer Inc: Product Portfolio

Table 43 Pfizer Inc: Key Developments

Table 44 Novartis AG: Overview

Table 45 Novartis AG: Product Portfolio

Table 46 Novartis AG: Key Developments

Table 47 Teva Pharmaceuticals Ltd: Overview

Table 48 Teva Pharmaceuticals Ltd: Product Portfolio

Table 49 Teva Pharmaceuticals Ltd: Key Developments

Table 50 Zydus Pharmaceuticals, Inc: Overview

Table 51 Zydus Pharmaceuticals, Inc: Product Portfolio

Table 52 Zydus Pharmaceuticals, Inc: Key Developments

Table 53 Sun Pharmaceuticals Industries Ltd: Overview

Table 54 Sun Pharmaceuticals Industries Ltd: Product Portfolio

Table 55 Sun Pharmaceuticals Industries Ltd: Key Developments

Table 56 Advanz Pharmaceuticals: Overview

Table 57 Advanz Pharmaceuticals: Product Portfolio

Table 58 Advanz Pharmaceuticals: Key Developments

Table 59 AdvaCare Pharma: Overview

Table 60 AdvaCare Pharma: Product Portfolio

Table 61 AdvaCare Pharma: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Cocaine Intoxication Drugs Market Value, 2021-2030 (US$ Million)

Figure 2 Global Cocaine Intoxication Drugs Market Share, By Drug Class, 2022 & 2030 (%)

Figure 3 Global Cocaine Intoxication Drugs Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 4 Global Cocaine Intoxication Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 5 Global Cocaine Intoxication Drugs Market Share, By Region, 2022 & 2030 (%)

Figure 6 Global Cocaine Intoxication Drugs Market Y-o-Y Growth, By Drug Class, 2022-2030 (%)

Figure 7 Diazepam Cocaine Intoxication Drugs Market Value, 2021-2030 (US$ Million)

Figure 8 Morphine Cocaine Intoxication Drugs Market Value, 2021-2030 (US$ Million)

Figure 9 Phentolamine Cocaine Intoxication Drugs Market Value, 2021-2030 (US$ Million)

Figure 10 Lorazepam Cocaine Intoxication Drugs Market Value, 2021-2030 (US$ Million)

Figure 11 Verapamil Cocaine Intoxication Drugs Market Value, 2021-2030 (US$ Million)

Figure 12 Global Cocaine Intoxication Drugs Market Y-o-Y Growth, By Route of Administration, 2022-2030 (%)

Figure 13 Intravenous Route of Administration in Global Cocaine Intoxication Drugs Market Value, 2021-2030 (US$ Million)

Figure 14 Nasal Route of Administration in Global Cocaine Intoxication Drugs Market Value, 2021-2030 (US$ Million)

Figure 15 Oral Route of Administration in Global Cocaine Intoxication Drugs Market Value, 2021-2030 (US$ Million)

Figure 16 Global Cocaine Intoxication Drugs Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)

Figure 17 Hospital Pharmacies Distribution Channel in Global Cocaine Intoxication Drugs Market Value, 2021-2030 (US$ Million)

Figure 18 Retail Pharmacies Distribution Channel in Global Cocaine Intoxication Drugs Market Value, 2021-2030 (US$ Million)

Figure 19 Online Pharmacies Distribution Channel in Global Cocaine Intoxication Drugs Market Value, 2021-2030 (US$ Million)

Figure 20 Global Cocaine Intoxication Drugs Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 21 North America Cocaine Intoxication Drugs Market Value, 2021-2030 (US$ Million)

Figure 22 Asia-Pacific Cocaine Intoxication Drugs Market Value, 2021-2030 (US$ Million)

Figure 23 Europe Cocaine Intoxication Drugs Market Value, 2021-2030 (US$ Million)

Figure 24 South America Cocaine Intoxication Drugs Market Value, 2021-2030 (US$ Million)

Figure 25 Middle East and Africa Cocaine Intoxication Drugs Market Value, 2021-2030 (US$ Million)

Figure 26 North America Cocaine Intoxication Drugs Market Value, 2021-2030 (US$ Million)

Figure 27 North America Cocaine Intoxication Drugs Market Share, By Drug Class, 2022 & 2030 (%)

Figure 28 North America Cocaine Intoxication Drugs Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 29 North America Cocaine Intoxication Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 30 North America Cocaine Intoxication Drugs Market Share, By Country, 2022 & 2030 (%)

Figure 31 South America Cocaine Intoxication Drugs Market Value, 2021-2030 (US$ Million)

Figure 32 South America Cocaine Intoxication Drugs Market Share, By Drug Class, 2022 & 2030 (%)

Figure 33 South America Cocaine Intoxication Drugs Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 34 South America Cocaine Intoxication Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 35 South America Cocaine Intoxication Drugs Market Share, By Country, 2022 & 2030 (%)

Figure 36 Europe Cocaine Intoxication Drugs Market Value, 2021-2030 (US$ Million)

Figure 37 Europe Cocaine Intoxication Drugs Market Share, By Drug Class, 2022 & 2030 (%)

Figure 38 Europe Cocaine Intoxication Drugs Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 39 Europe Cocaine Intoxication Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 40 Europe Cocaine Intoxication Drugs Market Share, By Country, 2022 & 2030 (%)

Figure 41 Asia-Pacific Cocaine Intoxication Drugs Market Value, 2021-2030 (US$ Million)

Figure 42 Asia-Pacific Cocaine Intoxication Drugs Market Share, By Drug Class, 2022 & 2030 (%)

Figure 43 Asia-Pacific Cocaine Intoxication Drugs Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 44 Asia-Pacific Cocaine Intoxication Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 45 Asia-Pacific Cocaine Intoxication Drugs Market Share, By Country, 2022 & 2030 (%)

Figure 46 Middle East & Africa Cocaine Intoxication Drugs Market Value, 2021-2030 (US$ Million)

Figure 47 Middle East & Africa Cocaine Intoxication Drugs Market Share, By Drug Class, 2022 & 2030 (%)

Figure 48 Middle East & Africa Cocaine Intoxication Drugs Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 49 Middle East & Africa Cocaine Intoxication Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 50 Tonix Pharmaceutical: Financials

Figure 51 GlaxoSmithKline Plc: Financials

Figure 52 Bristol Myers Squibb Company: Financials

Figure 53 Pfizer Inc: Financials

Figure 54 Novartis AG: Financials

Figure 55 Teva Pharmaceuticals Ltd: Financials

Figure 56 Zydus Pharmaceuticals, Inc: Financials

Figure 57 Sun Pharmaceuticals Industries Ltd: Financials

Figure 58 Advanz Pharmaceuticals: Financials

Figure 59 AdvaCare Pharma : Financials

세계 코카인 중독 치료제 시장 – 2023-2030

Global Cocaine Intoxication Drugs Market - 2023-2030